CLRB - Cellectar appoints interim chief medical officer

With the departure of John Friend as its chief medical officer, Cellectar Biosciences (NASDAQ:CLRB) has appointed former company consultant Laurence Reilly to the role in an interim capacity. Former CMO, Friend, is stepping down due to personal reasons, but he will serve the company through mid-November to facilitate the ongoing transition, Cellectar (CLRB) said. A consultant to Cellectar (CLRB) since early 2021, Reilly has run a consultant practice for biotech companies. Before that, he served as a chief scientific officer and vice president at Avillion, a drug development firm focused on co-development and financing of pharma candidates. Reilly will oversee the company’s clinical development program and report to the CEO, James Caruso. In August, Cellectar (CLRB) announced a commercial manufacturing and supply agreement with Evergreen Theragnostics for iopofosine I-131, a mid-stage candidate for Waldenstrom’s macroglobulinemia.

For further details see:

Cellectar appoints interim chief medical officer